HLA-G 14 bp In/Del and +3142 C/G genotypes are differentially expressed between patients with grade IV gliomas and controls

Página do item simplificado
dc.creatorKênia Cristina S.f.de Magalhães
dc.creatorEduardo a. Donadi
dc.creatorIstéfani Luciene da Silva
dc.creatorRenata t. Simões
dc.creatorKarla r. Silva
dc.creatorNathália a. Gomes
dc.creatorIbrahim Sadissou
dc.creatorGérvasio t. Carvalho
dc.creatorMarcelo a. Buzellin
dc.creatorLuciene s. Tafuri
dc.creatorCristiana Buzelin Nunes
dc.creatorMaurício b. Nunes
dc.date.accessioned2023-05-15T19:22:47Z
dc.date.accessioned2025-09-09T01:30:33Z
dc.date.available2023-05-15T19:22:47Z
dc.date.issued2021
dc.format.mimetypepdf
dc.identifier.doi10.1080/00207454.2020.1744593
dc.identifier.issn00207454
dc.identifier.urihttps://hdl.handle.net/1843/53385
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofInternational Journal of Neuroscience
dc.rightsAcesso Restrito
dc.subjectNeoplasias Encefálicas
dc.subjectGlioma
dc.subject.otherBrain tumors
dc.subject.otherGBM
dc.subject.otherHLA-G polymorphism
dc.subject.other3' UTR;
dc.subject.otherPlasma expression
dc.titleHLA-G 14 bp In/Del and +3142 C/G genotypes are differentially expressed between patients with grade IV gliomas and controls
dc.typeArtigo de periódico
local.citation.epage335
local.citation.issue4
local.citation.spage327
local.citation.volume131
local.description.resumoAim: Human Leukocyte Antigen-G (HLA-G) is a non-classical class I molecule that is involved in maternal–fetal immunotolerance. In cancer, this molecule contributes to the tumor escape. The aim of this study was to evaluate the 14 bp In/Del and þ3142 C > G polymorphisms of the HLAG 30 UTR and its relation with plasma and tissue HLA-G expression in patients with grade IV (high-grade) and grade I/II (low-grade) gliomas and controls. Patients and methods: Peripheral blood and tumor biopsies were collected from 85 patients with gliomas and blood samples from 94 controls. Polymorphisms were analyzed from blood DNA. Soluble HLA-G (sHLA-G) was measured by ELISA in plasma of the subjects and the tissue expression by immunohistochemistry on patient’s tissue. Results: Higher levels of sHLA-G were observed in grade IV gliomas patients than in controls (p < 0.0001). In grade IV patients, the heterozygous 14pb In/Del, þ3142 C/G genotypes and Del/C In/G haplotype were associated with higher sHLA-G levels (p < 0.0001) when compared with controls. GBM patients were stratified into high and low sHLA-G expression and an association was found between þ3142 C allele and high sHLA-G plasmatic levels (p ¼ 0.0095). Tissue HLA-G immunolabel was higher in high-grade than low-grade gliomas (p ¼ 0.0033). Conclusion: This was the first study evaluating HLA-G 30 UTR polymorphisms and expression in patients with gliomas. The 14 bp In/Del and þ3142 C/G genotypes and haplotypes showed high influence over sHLA-G expression, suggesting a heterozygous advantage in the tumor context and may contribute to a worse prognosis in glioma patients.
local.identifier.orcidhttps://orcid.org/0000-0002-5266-6870
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE ANATOMIA PATOLÓGICA E MEDICINA LEGAL
local.publisher.initialsUFMG
local.url.externahttps://www.tandfonline.com/doi/full/10.1080/00207454.2020.1744593

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG